sm-020
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 19, 2021 (NCT05136144)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06409195 | Phase 2 | Mar 25, 2024 | DermBiont, Inc. |
| NCT06099080 | Phase 2 | Nov 7, 2023 | DermBiont, Inc. |
| NCT06108024 | Phase 2 | Nov 6, 2023 | DermBiont, Inc. |
| NCT05136144 | Phase 2 | Oct 19, 2021 | DermBiont, Inc., Zepeda Dermatologia |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DermBiont, Inc. | For profit | 4 | 4 | 1 | 2021 |
| Zepeda Dermatologia | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1